Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
146-22-5
Molecular formula
C15H11N3O3
Molecular weight
281.27 g/mol
Drug class
Benzodiazepine hypnoticpositive allosteric modulator of GABAA receptors
Mechanism of action
Binds the benzodiazepine site on GABAA receptor complexes and enhances GABA-mediated chloride-channel opening, increasing neuronal inhibition and producing sedative, hypnotic, anxiolytic, muscle-relaxant and anticonvulsant effects.
Indications / reported uses
Short-term treatment of severe insomnia in countries where nitrazepam remains authorised
Some jurisdictions have historically used nitrazepam as an adjunctive anticonvulsant; exact indications and current availability are jurisdiction-specific
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Nitrazepam PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nitrazepam Permitted Daily Exposure (PDE) report (the Nitrazepam PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nitrazepam Occupational Exposure Limit (OEL) report (the Nitrazepam OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.